[Effects of anti-HPV16 E6-ribozyme on invasiveness of cervical carcinoma cell line CaSKi and vascular endothelial growth factor expression].
OBJECTIVE
To investigate the changes in the invasiveness of cervical cancer cell line CaSKi and the expression of vascular endothelial growth factor (VEGF) in response to treatment with anti-HPV16 E6-ribozyme, which plays a important role in the malignant phenotype and conversion of cervical cancer cells.


METHODS
By means of lipofectin transfection, anti- HPV16 E6-ribozyme and empty eukaryotic expression plasmids were respectively transfected into CaSKi cell line (designated as CaSKi-R and CaSKi-P respectively). CaSKi, CaSKi-R and CaSKi-P cells were observed for their cell growth curves, clone forming ability on soft agar and tumorigenicity in nude mice. One-step reverse transcriptional PCR (RT-PCR) was employed to examine the expression of VEGF.


RESULTS
No significant differences were found in the growth rate, clone forming ability and tumorigenicity between CaSKi and CaSKi-P cells. In contrast, CaSKi-R exhibited obviously decreased growth rate, clone forming ability and tumorigenicity (P<0.05). RT-PCR analysis showed that the expression levels of VEGF mRNA in CaSKi-R cells were lower than those in CaSKi-P and CaSKi cells.


CONCLUSIONS
Anti-HPV16 E6-ribozyme may reduce the proliferative ability and invasiveness of cervical cancer cell line CaSKi, possibly through decreasing VEGF expression in CaSKi cells.
Liu
Ke
K
Department of Obstetrics and Gynecology, Zhujiang Hospital, First Military Medical University, Guangzhou 510282, China. liuke76@yahoo.com.cn
Wang
Li-li
LL
Zheng
Yan-fang
YF
Zhang
Ji-ren
JR
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051379:Mice; D009361:Neoplasm Invasiveness; D009856:Oncogene Proteins, Viral / Q000037:antagonists & inhibitors*; D016337:RNA, Catalytic / Q000494:pharmacology*; D012097:Repressor Proteins / Q000037:antagonists & inhibitors*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D016337:RNA, Catalytic; D012097:Repressor Proteins; D042461:Vascular Endothelial Growth Factor A